Alentis Therapeutics key facts
- Operator of a clinical-stage biopharmaceutical company intended to offer various treatments for cancer and fibrotic diseases.
- It has raised $362.5M across 2 recorded rounds; the latest was Later Stage VC (Series D) ($181.4M) in Nov 2024.
- Notable investors include Bpifrance, RA Capital Management, High-Tech Gründerfonds, OrbiMed, Kinled Holding — 21 tracked in total.
- Status: Privately Held (backing).
Who backs Alentis Therapeutics
21+- ·The complete investor list: 21 names
- ·Watch Alentis Therapeutics: the Monday email on marks, rounds and moves
Alentis Therapeutics funding rounds
2 roundsHow much has Alentis Therapeutics raised?
Alentis Therapeutics has raised $362 million in total; 2 of its rounds are on record. The largest on record was an $181 million Series D in Nov 2024.
Alentis Therapeutics investors
21 investors are on record for Alentis Therapeutics, including Bpifrance, RA Capital Management, High-Tech Gründerfonds and OrbiMed. By type, the record holds 5 venture capital firms and 1 family office. The Series D in Nov 2024 drew 12 investors.
About Alentis Therapeutics
Operator of a clinical-stage biopharmaceutical company intended to offer various treatments for cancer and fibrotic diseases. The company develops innovative therapies for the treatment of cancer and other serious diseases, targeting immune checkpoints and modulating the immune system to enhance its ability to fight tumors, enabling medical researchers to treat liver fibrosis, cirrhosis, and liver cancer in patients.
- Industry
- Drug Discovery
- Sector
- Healthcare
- HQ
- Allschwil, Switzerland
- Founded
- 2019
- Employees
- 66
- Website
- alentis.ch/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.
Alentis Therapeutics doesn't have a valuation on record yet — one is published once a priced round, a reported valuation, fund marks, or secondary prints surface in our sources. The rest of the record below builds toward it.